Boao Innovation Holdings Has obtained a registration approval for static injection human immunoglobulin.

Guide: Static injection human immunoglobulin (pH4) developed by Hebei Da'an is mainly applicable to primary immunoglobulin deficiency.!----, Hebei Da'an Pharmaceutical Co., Ltd., a controlling subsidiary of Beijing Boyu Innovation Biotechnology Co., Ltd., developed a static injection human immunoglobulin (pH4) product, specification: 2.5g/bottle (5%, 50ml) recently received approval from the State Drug Administration to issue the "Drug Registration Certificate".Hebei Da'an research and development of static injection of human immunoglobulin (pH4) is mainly applicable to primary immunoglobulin deficiency, such as X interlocking low immunoglobulin emis, common variant immunodeficiency disease, immunoglobulin G subtype deficiency disease;Hebei Da'an this approved static injection human immunoglobulin (pH4) is the first in China in accordance with the "Drug Registration Management Measures" conducted a complete clinical study and related toxicology research static injection of human immunoglobulin products.product production is the first in China to adopt the most advanced 20nm nanofilm filter internationally accepted to remove the virus, the larger particles of the lipid envelope virus and the particle smaller non-lipid membrane virus have a good removal effect, can better ensure the safety of the product virus.clinical studies showed good clinical efficacy of related indications, and by analyzing the lgG subcategory of the product, the IgG subcategory in the product was complete, and the proportion was close to the IgG subclass distribution of normal human serum..